Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
Authors:
Open Access
- 1 November 2018
- journal article
- case report
- Published by Taylor & Francis in Lung Cancer: Targets and Therapy
- Vol. ume 9, 111-116
Abstract
ALK-rearranged lung cancer defines a distinctive molecular cohort of patients whose outcomes are significantly improved by the availability of ALK inhibitors. Thus, it is imperative for clinicians to screen appropriate patients for this driver mutation with a molecular testing platform capable of capturing all ALK fusions. Here, we report a novel VKORC1L1-ALK fusion and an ALK T1151K resistance mutation detected in a lung cancer patient who had been on crizotinib for over 8 years. Alectinib induced a dramatic response in this patient demonstrating its clinical activity against T1151K. This case illustrates the importance of performing repeat biopsy to explore mechanism(s) of resistance when patients experience disease progression on an ALK inhibitor. The approach has a direct therapeutic impact particularly when an ALK resistance mutation is identified.Keywords
This publication has 23 references indexed in Scilit:
- Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing ApproachesClinical Cancer Research, 2015
- A Novel Fusion of TPR and ALK in Lung AdenocarcinomaJournal of Thoracic Oncology, 2014
- HIP1–ALK, A Novel ALK Fusion Variant that Responds to CrizotinibJournal of Thoracic Oncology, 2014
- HIP1–ALK, a Novel Fusion Protein Identified in Lung AdenocarcinomaJournal of Thoracic Oncology, 2014
- Discovery of ALK‐PTPN3 gene fusion from human non‐small cell lung carcinoma cell line using next generation RNA sequencingGenes, Chromosomes and Cancer, 2012
- KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue OnlyPLOS ONE, 2012
- Crizotinib‐Resistant Mutants of EML4‐ALK Identified Through an Accelerated Mutagenesis ScreenChemical Biology & Drug Design, 2011
- KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung CancerClinical Cancer Research, 2009
- Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung CancerCell, 2007
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007